click below
click below
Normal Size Small Size show me how
Cardio 2 Drugs 1
| Generic | Brand | Indication | Class | Adult Dose | Black Box |
|---|---|---|---|---|---|
| amiodarone | Pacerone, Nexterone | Atrial fibrillation | Antiarrythmic Agent, Class III | 100 - 200 mg PO once daily | Life-threatening arrythmias (tablet) Pulmonary toxicity (tablet) Hepatotoxicity (tablet) Worsened arrhythmia (tablet) |
| amlodipine | Norvasc | Hypertension | CCB, Dihydropyridine | 2.5 - 10 mg PO once daily | None |
| amlodipine + benazepril | Lotrel | Hypertension | CCB, Dihydropyridine + ACE inhibitor | Amlodipine 2.5 - 10 mg/ Benazepril 10 - 40 mg PO once daily | Fetal toxicity |
| apixiban | Eliquis | Atrial fibrillation (stroke prevention), Venous Thromboembolism (VTE) prophylaxis and treatment | Anticoagulant, Factor Xa inhibitor | A Fib: 5 mg PO BID VTE treatment: 10 mg PO BID for 7 days followed by 5 mg PO BID VTE prophyalxis: 2.5 mg PO BID | Spinal/Epidural hematomas; Premature discontinuation increases the risk of thrombotic events |
| aspirin | None | Antiplatelet | Antiplatelet agent Nonsteroidal Anti-Inflammatory Drugs (NSAID) Salicylate | 81 mg PO once daily | None |
| antenolol | Tenormin | Hypertension | Beta-blocker, Beta-1 Selective | 50 - 100 mg PO per day | Cessation of Therapy (abrupt discontinuation can worsen cardiac conditions) |
| benazepril | Lotensin | Hypertension | ACE inhibitor | 10 - 40 mg PO per day | Fetal toxicity |
| bumetanide | Bumex | Edema or volume overload | Loop diuretic | 0.5 -2 mg PO/IV per day | Fluid/electrolyte loss |
| carvedilol | Coreg, Coreg CR | Hypertension, Heart failure with reduced ejection fraction | Beta-blocker with alpha blocking activity | IR: 3.125 - 25 mg PO BID ER: 20 - 80 mg PO once daily | None |
| clopidogrel | Plavix | Acute coronary syndrome Ischemic stroke | Antiplatelet, P2Y12 Inhibitor | 75 mg PO per day | Diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene |
| dabigatran | Pradaxa | Atrial fibrillation (stroke prevention), Venous Thromboembolism (VTE) prophylaxis and treatment | Anticoagulant, Direct thrombin inhibitor | A Fib: 150 mg PO BID VTE treatment: 150 mg PO BID | Thrombotic events, Spinal/Epidural hematoma |
| digoxin | Lanoxin | Atrial fibrillation Heart failure with reduced ejection fraction | Antiarrhythmic agent, Cardiac Glycoside | 0.0625 - 0.25 mg PO per day | None |
| diltiazem | Cardizem, Cardizem CD, Cardizem LA, Cartia XT | Atrial fibrillation | CCB, Nondihydropyridine Antiarrhythmic Agent, Class IV | IR: 120 - 480 mg per day in 3-4 divided doses ER: 120 - 480 mg PO per day in 1-2 divided doses | None |
| enalapril | Vasotec | Hypertension | ACE inhibitor | 5 - 40 mg PO per day | Fetal toxicity |
| enoxaparin | Lovenox | Venous Thromboembolism (VTE) prophylaxis and treatment | Anticoagulant, Low Molecular Weight Heparin | VTE Prophylaxis: 40 mg subcutaneously once daily VTE Treatment: 1 mg/kg subcutaneously Q12H | Spinal/Epidural hematoma |
| furosemide | Lasix | Edema or volume overload | Loop diuretic | 20 - 80 mg PO per day | Fluid/electrolyte loss |
| heparin | None | Atrial fibrillation (stroke prevention), Venous Thromboembolism (VTE) prophylaxis and treatment | Anticoagulant | VTE Prophylaxis: 5000 units subcutaneously Q8-12H VTE Treatment: 80 units/kg bolus followed by a continuous infusion of 18 units/kg/hour | None |
| labetalol | Normodyne, Trandate | Hypertension | Beta-blocker with alpha-blocking activity | 100 - 600 mg PO BID | None |
| lisinopril | Zestril | Hypertension | ACE inhibitor | 5 - 40 mg PO per day | Fetal toxicity |
| lisinopril + hydrochlorothiazide | Zestoretic | Hypertension | ACE inhibitor + Thiazide diuretic | Lisinopril 10-20 mg/Hydrochlorothiazide 12.5 - 25 mg PO per day | Fetal toxicity |
| metoprolol succinate | Toprol-XL | Hypertension, Heart failure with reduced ejection fraction | Beta-blocker, Beta-1 Selective | 12.5 - 200 mg PO per day | None |
| metoprolol tartrate | Lopressor | Hypertension | Beta-blocker, Beta-1 Selective | 25 - 200 mg PO BID | None |
| nebivolol | Bystolic | Hypertension | Beta-blocker, Beta-1 Selective | 5 - 40 mg PO per day | None |
| potassium chloride | Klor-Con, K-Dur, Micro-K | Hypokalemia | Electrolyte supplement | 10 - 80 mEq PO per day in 1-4 divided doses | None |
| propranolol | Inderal LA, Inderal XL | Hypertension | Beta blocker, non-selective | 80 - 160 mg PO per day in 1-4 divided doses (based on IR or ER formulation) | None |
| ramipril | Altace | Hypertension | ACE inhibitor | 2.5 - 20 mg PO per day in 1-2 divided doses | Fetal toxicity |
| rivaroxaban | Xarelto | Atrial fibrillation (stroke prevention), Venous Thromboembolism (VTE) prophylaxis and treatment | Anticoagulant, Factor Xa inhibitor | A Fib: 20 mg PO per day VTE treatment: 15 mg PO BID for 21 days followed by 20 mg PO per day VTE prophylaxis: 10 mg PO once | Spinal/Epidural hematomas; Premature discontinuation increases the risk of thrombotic events |
| ticagrelor | Brilinta | Acute coronary syndrome | Antiplatelet, P2Y12 Inhibitor | 90 mg PO BID | Bleeding Risk; Diminshed antiplatelet effect when given in combination with aspirin doses > 100 mg daily |
| torsemide | Demadex | Edema or volume overload | Loop diuretic | 5 - 50 mg PO per day | None |
| verapamil | Calan SR, Verelan, Verelan PM | Atrial fibrillation | CCB, Nondihydropyridine Antiarrhythmic Agent, Class IV | IR: 120 - 480 mg PO per day in 3-4 divided doses ER: 120 - 480 mg PO once daily | None |
| warfarin | Coumadin | Atrial fibrillation (stroke prevention), Venous Thromboembolism (VTE) treatment | Anticoagulant, Vitamin K Antagonist | 1-10 mg PO once daily - Individualized dosing | Bleeding Risk |